Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 1 |
2024 | 3 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean
metro group[Corporate Author]
(103 results)?
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
JAMA Netw Open. 2024 Mar 4;7(3):e241215. doi: 10.1001/jamanetworkopen.2024.1215.
JAMA Netw Open. 2024.
PMID: 38446479
Free PMC article.
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
Maiorano BA, De Giorgi U, Verzoni E, Maiello E, Procopio G, Conteduca V, Di Maio M; MeetURO group.
Maiorano BA, et al.
Target Oncol. 2024 Jan;19(1):1-11. doi: 10.1007/s11523-023-01016-x. Epub 2023 Nov 22.
Target Oncol. 2024.
PMID: 37993604
Free PMC article.
Item in Clipboard
Correction to: Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis.
Maiorano BA, De Giorgi U, Verzoni E, Maiello E, Procopio G, Conteduca V, Di Maio M; MeetURO group.
Maiorano BA, et al.
Target Oncol. 2024 Jan;19(1):127. doi: 10.1007/s11523-023-01025-w.
Target Oncol. 2024.
PMID: 38070004
Free PMC article.
No abstract available.
Item in Clipboard
Cite
Cite